diabetes) or neurologic disease , peripheral vascular disease, o r psychiatric illness/social situations) (28) Have insufficient peripheral v enous access to permit completion of the study dosing and compliance with study phlebotomy regimen (29) Have a history of alcohol depe ndence or use of illicit drugs that could potentially interfere with adherence to study procedures or requirements (e. g. opioids, cocaine, amphetamines, hallucino gens, etc.) Dose eligibility: Subjects must have adequate organ function as defined by the laboratory values in Table 1 before dosing of CRS-207. Laboratory tests may be done up to 3 days prior to CRS-207 dosi ng or 2 days prior to Cy for subjects receiving Cy. Delayed doses will be discussed with the medical monitor.